Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Placebo Effect01:54

The Placebo Effect

7.1K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
7.1K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.0K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.0K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Long-term Depression01:05

Long-term Depression

33.8K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.8K
Long-term Depression01:03

Long-term Depression

3.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.6K
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

1.1K
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRD.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Is there an independant anti-suicidal effect of esketamine in treatment resistant depression?

Journal of affective disorders·2026
Same author

The influence of CHRNA5 and D398N missense variation on social and emotional behaviors in rodents and humans.

Translational psychiatry·2025
Same author

Association Between Metabolic Syndrome, Obesity, and Cognitive Performances in Individuals With Bipolar Disorders: Cross-Sectional and Longitudinal Analyses in the FACE-BD Cohort.

Acta psychiatrica Scandinavica·2025
Same author

Substance use disorders in outpatients with bipolar disorder and pain complaints.

Journal of affective disorders·2025
Same author

Hippocampal connectivity changes after traumatic memory reactivation with propranolol for posttraumatic stress disorder: a randomized fMRI study.

European journal of psychotraumatology·2025
Same journal

Corrigendum to "Effects of neuronavigation-guided rTMS on serum BDNF, TrkB and VGF levels in depressive patients with suicidal ideation" [J. Affect. Disord. 323 (2023) 617-623].

Journal of affective disorders·2026
Same journal

Transcutaneous vagus nerve stimulation enhances reward-effort efficiency in severe major depressive disorder.

Journal of affective disorders·2026
Same journal

Age-varying associations between attitudes toward suicide and suicidal ideation in Chinese psychiatric outpatients.

Journal of affective disorders·2026
Same journal

Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Journal of affective disorders·2026
Same journal

The perils of perfection: A prospective population-based cohort study of perfectionism and depression in young adults.

Journal of affective disorders·2026
Same journal

Dissociable patterns of alpha-band connectivity and structural-functional coupling in major depressive disorder with mixed features.

Journal of affective disorders·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

869

An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness.

P Gorwood1, K Demyttenare2, G Vaiva3

  • 1Centre hospitalier Sainte-Anne & Paris Descartes University, CMME, Paris, France; Centre de Psychiatrie et Neurosciences (CPN), INSERM UMR894, Paris, France.

Journal of Affective Disorders
|July 11, 2015
PubMed
Summary
This summary is machine-generated.

Early increases in joy, not just reduced sadness, predict depression treatment success. Measuring joy frequency early in treatment can help identify patients likely to respond to therapy.

Keywords:
AgomelatineEmotionJoyMajor depressive disorderPredictionSadnessTreatment response

More Related Videos

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.4K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

23.1K

Related Experiment Videos

Last Updated: Apr 7, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

869
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.4K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

23.1K

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Affective Science

Background:

  • Early positive emotion improvement predicts depression treatment response.
  • Replication with simpler assessments is needed for clinical practice.

Purpose of the Study:

  • To assess if early improvement in positive emotions, specifically joy, predicts treatment response in depressed outpatients.
  • To compare the predictive value of joy improvement versus sadness decrease.

Main Methods:

  • 2049 adult outpatients with depression receiving agomelatine were assessed.
  • Evaluations included clinician-rated scales and the Multidimensional Assessment of Thymic States (MATHYS) auto-questionnaire.
  • MATHYS measured the frequency of emotions like joy and sadness at baseline, week 2, and week 6.

Main Results:

  • Increased joy at week 2 was more specific (85.04%) and had a higher positive predictive value (70.55%) for treatment response than decreased sadness.
  • Early improvement in joy better predicted clinical and functional remission compared to clinical response.
  • Joy showed lower correlation with clinical severity than sadness at baseline.

Conclusions:

  • Early improvement in joy during the first two weeks of treatment is a strong predictor of treatment response and remission.
  • The frequency of joy is a valuable predictive measure for depression.
  • Further study is warranted for including joy frequency in depression rating scales.